Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2011-05-24 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Pharmaxis Receives Negative Bronchitol Trend Vote from CHMP 2 pages 94.7KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 25 May 2011 from Pharmaxis Ltd regarding a negative trend vote from the Committee for Medicinal Products for Human Use (CHMP) on their marketing application for Bronchitol. It discusses regulatory review status, potential appeal processes, and strategic implications for the company. The content is an announcement about regulatory developments and company plans, not a financial report, earnings release, or detailed investor presentation. It does not contain financial statements or detailed financial data. The document is a regulatory update or announcement related to the company's regulatory filings and strategy. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2011-05-24 English
Investor Conference Call 1 page 60.4KB
Regulatory Filings Classification · 95% confidence The document is a media release announcing an upcoming investor teleconference to discuss an update related to a European marketing application. It provides details for a conference call and mentions a recording will be available later. There is no substantive financial data, no detailed report, and no transcript of the call itself. The document is essentially an announcement of an event (conference call) rather than the call transcript or a financial report. Therefore, it fits best as a Call Transcript (CT) category only if it contained the full transcript, but since it only announces the call, it is not a transcript. It is also not an investor presentation (IP) because it lacks presentation content. Given the options, the best fit is Call Transcript (CT) only if the transcript is included, but here it is not. The document is a media release about a conference call, so the closest category is Call Transcript (CT) if the transcript was included, but since it is not, the fallback is Regulatory Filings (RNS). However, the instructions specify to classify full transcripts as CT, and announcements of calls as RNS. Since this is an announcement of a call, not the transcript, the correct classification is Regulatory Filings (RNS).
2011-05-23 English
Additional Background to Appendix 3Y Filed 18 May 2011 2 pages 90.4KB
Director's Dealing Classification · 95% confidence The document is a media release providing additional background information related to an Appendix 3Y filing, which is a Change of Director's Interest Notice. It discusses the sale of shares by the CEO to cover a tax liability from exercising options. The content focuses on insider share transactions and compliance with trading policies. There are no financial statements, earnings data, or report attachments. The document is not a full audit report, annual report, or earnings release. It is specifically about a director's dealing in shares, which fits the category of Director's Dealing (DIRS). The document length is short and it is a standalone announcement about insider share transactions, confirming the classification as DIRS with high confidence.
2011-05-23 English
Trading Halt 2 pages 162.3KB
Regulatory Filings Classification · 95% confidence The document is a market release dated 23 May 2011 from Pharmaxis Ltd announcing a trading halt of its securities pending an upcoming announcement related to its European marketing application for a product. The text is short (1862 characters) and primarily serves as a notification to the exchange and investors about the trading halt and the reason for it. There is no financial data, report content, or detailed analysis present. It is not a report itself but an announcement about a trading halt event. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2011-05-22 English
Change of Director`s Interest Notice 3 pages 110.4KB
Director's Dealing Classification · 100% confidence The document is an Appendix 3Y form, which is a Change of Director's Interest Notice. It details the sale of shares by a company director, including the number of shares disposed, the price, and the resulting holdings. The document references ASX listing rules and the Corporations Act, indicating it is a regulatory disclosure of insider trading activity by a director. It does not contain financial performance data, management discussion, or other report content. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is under 5,000 characters and is a direct notice of a director's share transaction, not an announcement of a report or a certification. Therefore, the correct classification is DIRS with high confidence.
2011-05-17 English
Appendix 3B: Exercise of Employee Options 11 pages 106.4KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It details the issuance of fully paid ordinary shares upon exercise of options under the company's Employee Option Plan. The document includes specific information about the number of securities issued, their class, exercise prices, expiry dates, and the purpose of the issue. This type of document is a formal announcement related to share issuance and capital changes rather than a financial report or earnings release. It aligns with the definition of a Share Issue/Capital Change announcement (SHA). The document length is substantial (15,000 characters), but the content is focused on the issuance of shares and options, not on financial results or management discussion. Therefore, the correct classification is SHA with high confidence.
2011-04-26 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.